WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 6 fonti

Servier to buy Edgewise Therapeutics' muscular dystrophy drug

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

Raccontata da

biopharmadive.com

pharmaceutical-technology.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mesi fa

Servier to buy Edgewise Therapeutics' muscular dystrophy drug

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

Timeline cronologica

lunedì 1 giugno 2026·biopharmadive.com
Servier buys into muscular dystrophy with potentially $2.7B deal
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.
lunedì 1 giugno 2026·statnews.com
Servier to buy Edgewise Therapeutics' muscular dystrophy drug
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

1 mesi fa

Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets

Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year's end.

Leggi questa versione → originale

pharmaceutical-technology.com1 mesi fa

Servier to buy Edgewise's muscular dystrophy business for $2.65bn

Servier buys Edgewise's muscular dystrophy business for $2.65bn upfront, securing sevasemten (Phase II rare-disease candidate for Duchenne/Becker dystrophy). Highlights biotech M&A consolidation toward regulatory-gated, high-value rare assets; pharma valuations hinge on long-term compliance milestones, reshaping IT infrastructure demand in healthcare sector.

Leggi questa versione → originale

biopharmadive.com1 mesi fa

Servier buys into muscular dystrophy with potentially $2.7B deal

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.

Leggi questa versione → originale

investors.com1 mesi fa

This Biotech Snatched Up $1.55 Billion And Removed A Key Overhang

Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business.

Leggi questa versione → originale

lemonde.fr1 mesi fa

Le laboratoire Servier mise 1,33 milliard d’euros sur des traitements contre les dystrophies musculaires

Le groupe pharmaceutique français rachète l’activité dystrophie musculaire de l’américain Edgewise Therapeutics, incluant un traitement expérimental contre les maladies de Duchenne et de Becker.

Leggi questa versione → originale

lunedì 1 giugno 2026·

endpoints.news

Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets

Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an experimental neuromuscular medicine that could have…

lunedì 1 giugno 2026·

investors.com

This Biotech Snatched Up $1.55 Billion And Removed A Key Overhang

Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business.

lunedì 1 giugno 2026·

lemonde.fr

Le laboratoire Servier mise 1,33 milliard d’euros sur des traitements contre les dystrophies musculaires

Le groupe pharmaceutique français rachète l’activité dystrophie musculaire de l’américain Edgewise Therapeutics, incluant un traitement expérimental contre les maladies de…

martedì 2 giugno 2026·

pharmaceutical-technology.com

Servier to buy Edgewise's muscular dystrophy business for $2.65bn

Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.